Plasmodin

Quick links to important sections

Plasmodin

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Plasmodin

Quick Facts

Property Description
Active Ingredient(s) Pyrimethamine, Sulfadoxine
Form Oral tablet, Dispersible tablet
Pharmacological Class Antimalarial Agent, Antiprotozoal
General Purpose To stop the growth of parasitic organisms
Origin Synthetic

The Identity and Classification of Plasmodin

Plasmodin is a synthetic, fixed-dose combination (FDC) medicine officially classified as an Antimalarial Agent and Antiprotozoal. This preparation is typically supplied as an oral tablet, intended for the oral route of administration. The combination of Pyrimethamine and Sulfadoxine is also internationally recognized by the brand name Fansidar, and is clinically recognized for its long-acting profile, which is beneficial in regions where consistent dosing is challenging.

The drug entity is defined by the precise combination of its two active ingredients into a single dosage form. Unlike antimalarials that feature a single active component, Plasmodin belongs to the unique antifolate drug combination class. The use of this FDC is a differentiating factor, as it is often reserved for populations where resistance to common first-line treatments is a significant concern.

Composition and General Purpose of the Antifolate Combination

Plasmodin's composition features Pyrimethamine, an inhibitor of dihydrofolate reductase, and Sulfadoxine, which is a long-acting sulfonamide antibiotic (sulfa drug). The essential purpose of this combined formulation is to stop the proliferation of parasitic organisms by chemically undermining their ability to grow and multiply.

The simultaneous action of the two agents creates a sequential metabolic blockade on the parasite’s ability to utilize folic acid, a compound necessary for its DNA and protein creation. This antimalarial combination is known for achieving a powerful synergistic effect against the target organism, supporting the drug's reliable ability to interrupt the parasite's life cycle.

Regulatory References

  1. NIH LiverTox

What side effects are possible with Plasmodin?

Possible Side Effects and Safety Information

The official safety profile for Plasmodin (Pyrimethamine and Sulfadoxine) is structured around potential adverse reactions and safety constraints, primarily emphasizing risks related to its components: a long-acting sulfonamide and an antifolate agent. Regulatory bodies classify reactions by severity, frequency, and the specific organ systems involved.


Documented Adverse Reaction Categories

Adverse reactions are formally grouped by the body systems they affect, with the official labeling focusing on three main categories:

  • Blood and Lymphatic System Disorders: Potential for severe hematologic effects, including agranulocytosis, aplastic anemia, and megaloblastic anemia. These risks are more frequently associated with long-term suppressive therapy.
  • Skin and Subcutaneous Tissue Disorders: Includes the risk of serious cutaneous adverse reactions (SCARs). Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) are explicitly listed as rare but potentially fatal serious adverse reactions. These severe dermatologic effects typically appear early in treatment.
  • Gastrointestinal and Hepatobiliary Disorders: Commonly reported effects include nausea, vomiting, anorexia, and abdominal discomfort. Rare but serious risks include hepatic necrosis and acute hepatic failure.

Safety Constraints and Special Populations

Safety constraints are defined for specific situations and populations:

  • The medicine is contraindicated in infants under 2 months of age due to the risk of kernicterus (bilirubin-induced brain damage) from the sulfonamide component.
  • It is restricted for use in individuals with known hypersensitivity to Sulfonamides or Pyrimethamine, and those with pre-existing conditions like severe megaloblastic anemia or severe hepatic/renal impairment.

Overdose and Emergency Response

Overdose involving Plasmodin (Pyrimethamine/Sulfadoxine) is officially documented in regulatory information to affect the Central Nervous System (CNS), Gastrointestinal, and Hematologic systems. Manifestations of acute overdose often begin with severe and repeated vomiting, anorexia, and agitation, rapidly progressing to signs of neurotoxicity such as convulsions and hallucinations. Life-threatening outcomes, including circulatory collapse and respiratory depression, have been documented in official labeling, and fatalities are reported, particularly as infants and children are extremely susceptible to the drug's effects.

Emergency Actions Required

  • Seek emergency medical attention immediately. The patient must be urgently transferred to a specialized unit for close monitoring.
  • Management involves supportive and symptomatic measures. Procedural steps officially documented include gastric lavage (if performed very soon after ingestion) and administration of activated charcoal.
  • While no specific antidote is known for the pyrimethamine component of the medicine, Folinic acid (Leucovorin) may be used to address hematologic toxicity.
  • Monitoring of blood counts, liver, and renal function is required repeatedly for up to four weeks due to the risk of delayed hematologic changes like megaloblastic anemia.

Therapeutic Uses of Plasmodin

What Plasmodin Treats: Main Uses and Benefits

Plasmodin is commonly used across domains where additional symptomatic support is needed, primarily in the management of parasitic infections. It is commonly used for managing acute, uncomplicated Plasmodium falciparum malaria, and is applied in settings where conditions involve a need for specific, targeted antimalarial support. This treatment is relevant for easing symptoms related to systemic imbalance and heightened physiological activity, such as symptoms related to physical discomfort, symptoms of increased neurological or muscular activity, and symptoms that interfere with daily functioning.

Beyond acute care, the medication is considered relevant in contexts involving recurrent or episodic manifestations. The primary therapeutic indications include managing acute malaria in resistant areas, providing suppressive maintenance for infections like toxoplasmosis, and being utilized in Intermittent Preventive Treatment in Pregnancy (IPTp). This application provides support that helps ease the overall symptom burden and contributes to improved comfort during episodes where symptoms may intensify temporarily.


Quick Fact: Relief for Acute Systemic Symptoms
Common Clinical Contexts Conditions involving acute parasitic infection, suppressive maintenance, and preventive treatment in high-risk zones.
Symptom Categories Symptoms related to systemic imbalance, acute febrile symptoms, physical discomfort, and symptoms that interfere with daily functioning.
Patient Benefit Provides support that helps ease the overall symptom burden and contributes to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Plasmodin — Official Regulatory Information

Official regulatory documents define strict population eligibility for the pyrimethamine and sulfadoxine combination.


Contraindicated Populations

The medicine is contraindicated and must not be used by:

  • Patients with documented megaloblastic anemia due to folate deficiency.
  • Individuals with known hypersensitivity to pyrimethamine or sulfonamide drugs.
  • Infants less than 2 months of age.
  • Women at term of pregnancy (for prophylactic use) and during the nursing period (breastfeeding).

Age and Condition-Based Restrictions

Category Regulatory Status
Age (Allowed) Approved for use in children older than 2 months and adults.
Organ Failure Repeated prophylactic use is contraindicated in patients with renal failure or hepatic failure.
Pregnancy Not recommended during the first trimester; conditional use is established for IPTp during the second and third trimesters.

Use requires caution in patients with conditions such as impaired renal or hepatic function, G6PD deficiency, blood dyscrasias, severe allergy, or bronchial asthma. The drug should generally not be given if the patient has received the combination in the past 30 days.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Plasmodin's official interaction profile is structured around pharmacodynamic constraints, primarily concerning the antifolate mechanism of its active ingredients, Pyrimethamine and Sulfadoxine.

Documented Interaction Restrictions

Category Interacting Substances Official Constraint
Contraindicated Combinations Trimethoprim, Sulfamethoxazole/Trimethoprim, other Sulfonamides Use is restricted or advised to be avoided due to the additive antifolate effect that increases the risk of hematological side effects
Pharmacodynamic Reinforcement Antifolic drugs (e.g., Methotrexate, Zidovudine, Proguanil), Chloroquine Risk of bone marrow suppression is potentiated; risk of adverse reactions may be increased (Chloroquine)
Supplement Interaction Folic acid (ge 5 mg daily) Must not be given concomitantly as it formally counteracts the efficacy of the antimalarial agent

Co-administration with drugs having hepatic or hematological toxicity should be approached with caution in patients with impaired renal or hepatic function. This is due to the potential for the accumulation of the drug and other toxic agents, leading to a heightened risk of adverse outcomes, as documented in regulatory guidelines. The official label also notes that Plasmodin has not been reported to interfere with the function of antidiabetic agents.

Mechanism of Action

Sequential Blockade of Parasite Folate Biosynthesis

Plasmodin's mechanism of action relies on a sequential metabolic blockade of the parasite's essential folate biosynthesis pathway. The component Sulfadoxine competitively inhibits the Dihydropteroate Synthase (DHPS) enzyme, while Pyrimethamine subsequently and selectively inhibits the Dihydrofolate Reductase (DHFR) enzyme. This dual molecular targeting is critical because the parasite requires an intact folate pathway to produce the active cofactor, Tetrahydrofolic Acid (THFA), necessary for its growth and replication.


Synergistic Arrest of Nucleic Acid Synthesis

The combined effect is synergistic, meaning the two components have a magnified effect together compared to their individual activities. By severely depleting the supply of THFA cofactors, the drug effectively arrests the production of DNA and RNA precursors. This molecular cascade translates into the immediate physiological consequence of halting parasite cell division (schizonticidal action) in the bloodstream, leading to the clearance of asexual parasites. The mechanism is functionally less effective or inactive against the non-dividing, dormant hypnozoites or the parasite's early liver stages.

Dosage and Administration Information

How to Use Plasmodin: Official Administration Guidelines

The usage of Plasmodin, a fixed-dose combination of Sulfadoxine and Pyrimethamine, is determined by strict administration protocols outlined in official documentation. The standard formulation is an oral tablet for adults, but a dispersible tablet is available for pediatric patients. All approved use is limited to the oral route of administration.

Administration patterns fall into two distinct categories: single-dose treatment and scheduled prevention. For the management of acute cases, the standard adult regimen is a single oral dose of 2 to 3 tablets (1000/50 mg to 1500/75 mg). For malaria prophylaxis, the typical dose is 1 tablet (500/25 mg) administered once weekly.

Procedural and Contextual Instructions

Administration Principle Official Regulatory Guidance
Intake Condition The standard tablet must be swallowed whole and is officially directed to be taken with or immediately after food to mitigate potential gastric irritation.
Pediatric Dosing Dosage for children is calculated strictly based on body weight. If a child vomits the dose within 30 minutes of administration, official guidelines specify giving a full replacement dose after a 30-minute rest.
Duration of Use Prophylaxis for travelers should begin 1 to 2 days before arrival and must continue for 4 to 6 weeks after leaving the area. For Intermittent Preventive Treatment in Pregnancy (IPTp), doses are given at intervals of at least one month apart, starting from the second trimester.

These official instructions define a clear procedural structure for administration, ensuring the drug is used according to its approved route and standardized, context-dependent dosing schedules as defined by authorities.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Plasmodin

Evidence for Use in Intermittent Preventive Treatment in Pregnancy (IPTp)

Research exploring the use of Plasmodin as an Intermittent Preventive Treatment in Pregnancy (IPTp) was studied for circumstances related to malaria risk in women living in high-transmission areas. This evidence is derived largely from high-level research, including Randomized Controlled Trials (RCTs), Systematic Reviews, and large-scale Meta-Analyses. These studies focused primarily on outcomes related to systemic or functional imbalance linked to malaria infection and the health of the mother and infant. Findings describe patterns observed in the studies where the use of the regimen was associated with measurements such as higher mean birth weight in the observed populations. However, official sources note that findings were mixed and that reported outcomes are often linked to geographic differences in parasite resistance levels.


Evidence for Use in Acute, Uncomplicated Malaria

The research into Plasmodin for the management of acute, uncomplicated malaria includes Clinical Trials and Efficacy Surveillance Studies that were evaluated in regions with specific parasite sensitivities. These studies primarily focused on outcomes describing episodic or acute changes, such as the speed of parasite clearance and the resolution of acute symptoms related to heightened physiological strain. Regulatory documentation describes patterns where the medicine was observed in clinical settings as a therapeutic option. However, as research continued, data show patterns related to increasing treatment failure rates in areas where the parasite developed resistance to the antifolate components. The evidence contributes to the broader evidence landscape, but the findings must be considered alongside the variability in parasite resistance encountered across different parts of the world.


What Research Indicates Remains Uncertain

Research highlights what is known — and what is still uncertain — regarding Plasmodin. A major limitation is that the evidence quality varies across studies due to widespread global parasite resistance. How the medicine performed appears to be highly dependent on the geographical location of the study, meaning that research findings do not determine whether an individual will respond similarly in a different area. Comparative evidence is lacking for the medicine against many current first-line therapies. Furthermore, existing research is limited in assessing the impact on chronic tissue cyst stages of the Toxoplasma parasite, and the potential effects of unpredictable drug concentrations on long-term treatment success are not fully established.

Key Studies & References

  1. Intermittent preventive treatment for malaria in pregnancy using sulfadoxine-pyrimethamine: a systematic review and meta-analysis of randomized controlled trials
  2. Pyrimethamine/Sulfadoxine Combination – LiverTox: Clinical and Research Information on Drug-Induced Liver Injury (NIH source for drug identity and use context)

Frequently Asked Questions (FAQ)

Common questions about Plasmodin (FAQ)

Q: Why do doctors prescribe Plasmodin for more than one condition?

Plasmodin’s primary purpose, according to regulatory documents, is described as stopping the growth of parasitic organisms. Because the drug targets a fundamental metabolic process, it is studied for multiple applications. Official documents indicate it is prescribed for the treatment and prevention of certain types of malaria, and sometimes in combination with other agents for the management of toxoplasmosis.


Q: What specific conditions is Plasmodin officially approved to treat?

Plasmodin, which is a combination of Sulfadoxine and Pyrimethamine, is officially indicated for the treatment of acute uncomplicated P. falciparum malaria. It is also indicated for use in specific regimens designed for the prevention (prophylaxis) of malaria in certain areas, as described in regulatory documentation.


Q: How quickly should I expect to feel a change after starting Plasmodin?

Official information regarding the drug’s behavior in the body (pharmacokinetics) indicates that the components are well-absorbed. The peak concentrations of the active ingredients typically occur between an hour and a half and eight hours after taking a dose. The components also have long half-lives, meaning they remain present in the body for an extended period of time.


Q: Is there a timeline for when the medicine is supposed to start working?

In studies, the concentrations of the active ingredients in the blood typically reach their highest point between 1.5 and 8 hours after the medicine is taken. Because the components have long half-lives (up to six days for Pyrimethamine), the medication remains present in the body for an extended time.


Q: What happens if someone forgets to take a dose of Plasmodin?

Official consumer information provides specific instructions for managing a missed dose. These guidelines are designed to help ensure the correct amount of medicine is taken and that double doses are avoided. Full details are found in the official patient information section, 'How to Use Plasmodin.'


Q: Can Plasmodin cause changes in mood or behavior?

Yes, official safety labeling includes Central Nervous System reactions among the reported adverse effects. These reactions can involve changes in mood and behavior, such as mental depression, apathy, nervousness, and hallucinations.


Q: Are headaches a normal side effect when starting Plasmodin?

Headache is listed in official documents as a commonly reported side effect associated with the use of this medicine. Official product information contains a complete list of reported reactions, including headaches.


Q: Does Plasmodin affect sleep patterns?

Yes, official product information reports that this medicine may affect sleep patterns. Difficulty sleeping, also referred to as insomnia, is listed among the reported side effects.


Q: Can using alcohol while taking Plasmodin cause problems?

Official patient information notes that alcohol consumption should be avoided or approached with caution when using this medicine. This is because alcohol may potentially increase the risk of certain side effects, such as dizziness.


Q: Is Plasmodin safe for use while breastfeeding?

Official product labeling advises against the use of this medicine while breastfeeding. The sulfonamide component of the drug carries a risk of a condition called kernicterus (bilirubin-induced brain damage) in the infant. Use is typically avoided, especially if the infant is ill, premature, or has specific underlying health conditions.


Q: Why is Plasmodin sometimes stopped suddenly by a healthcare provider?

Regulatory warnings require that the medicine be discontinued immediately if specific severe reactions occur. This includes the first sign of a skin rash, or if a significant reduction in the body's blood cell counts is noted. Immediate cessation may also be required upon the occurrence of an active bacterial or fungal infection.


Q: Is it normal to feel slightly dizzy when first taking Plasmodin?

Dizziness is listed in the official documents among the commonly reported side effects associated with Plasmodin. This is a recognized effect of the medicine.


Q: How does Plasmodin affect my ability to drive or operate machinery?

The medicine may cause side effects that could potentially affect one’s ability to perform tasks requiring focus. Since adverse reactions such as dizziness, confusion, or visual disturbances are reported, official information indicates that caution is necessary when driving or operating heavy machinery.


Q: Is it true that Plasmodin is an 'old' medicine?

The active components of Plasmodin have been in medical use for decades. For instance, Pyrimethamine, one of the two main active ingredients, was developed and introduced for medical use in the 1950s. This gives the medicine a long history of clinical study.


Q: What kind of monitoring or tests might be needed while taking Plasmodin?

Official labeling states that regular monitoring of blood cell counts, including platelet counts, is required, particularly when taking the medicine for a long period of time. Furthermore, tests on urine and kidney function may be performed for patients with pre-existing kidney issues.

How should Plasmodin be stored and disposed of?

How to Store and Dispose of Plasmodin?

Official regulatory labeling dictates specific conditions to maintain the stability and safety of Plasmodin (Pyrimethamine/Sulfadoxine).

Storage Requirements

Temperature: The medication must be stored at controlled room temperature, specifically below 30°C (86°F).

Protection and Container: Store the tablets in the original container and keep it tightly closed to protect it from excessive moisture. Storage should be out of the sight and reach of children.

Disposal Instructions

The primary method for discarding unused or expired Plasmodin is through a drug take-back program. If a program is unavailable, the official guidance permits disposal in household trash after mixing the tablets with an undesirable substance, such as dirt or used coffee grounds, and placing the mixture in a sealed container. The medication must not be flushed down the toilet or poured down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Plasmodin found in:

A-Z Index: